SERC

This brand name is authorized in Austria, Canada, France, Ireland, Mexico, New Zealand, South Africa, Spain, Tunisia, UK.

Active ingredients

The drug SERC contains one active pharmaceutical ingredient (API):

1	Betahistine UNII 49K58SMZ7U - BETAHISTINE HYDROCHLORIDE
	Betahistine dihydrochloride is a histamine-like drug in which pharmacological activity can be attributed to a specific effects and/or more direct influences on recovery mechanisms the vestibular nuclei. It has weak agonist activity at histamine H1 receptors and moderate antagonist activity at H3 receptors. Betahistine may increase blood flow to the cochlear region as well as to the whole brain.
	Read more about Betahistine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SERC Tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N07CA01	Betahistine	N Nervous system → N07 Other nervous system drugs → N07C Antivertigo preparations → N07CA Antivertigo preparations
Discover more medicines within N07CA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02243878, 02247998
ES	Centro de información online de medicamentos de la AEMPS	55296, 57257, 64130, 78431, 84344
FR	Base de données publique des médicaments	66362637
GB	Medicines & Healthcare Products Regulatory Agency	146735, 181849, 26034, 26073, 381668
IE	Health Products Regulatory Authority	45527, 45594, 56654
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	75796
NZ	Medicines and Medical Devices Safety Authority	8491, 8492
TN	Direction de la Pharmacie et du Médicament	9253071
ZA	Health Products Regulatory Authority	38/5.6/0040